Alzamend Neuro Files 8-K on Equity Sales
Ticker: ALZN · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, financials, sec-filing
TL;DR
Alzamend sold unregistered equity, check financials.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on September 25, 2025, reporting unregistered sales of equity securities and financial statements. The company, incorporated in Delaware, is involved in Pharmaceutical Preparations.
Why It Matters
This filing indicates potential dilution for existing shareholders due to unregistered equity sales and provides updated financial information.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can lead to dilution and potential regulatory scrutiny.
Key Numbers
- 001-40483 — SEC File Number (Identifier for Alzamend Neuro, Inc.)
- 811822909 — EIN (Employer Identification Number)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- September 25, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What specific type of equity securities were sold unregistered?
The filing does not specify the exact type of equity securities sold unregistered, only that such sales occurred.
Were these unregistered sales part of a private placement or other offering?
The filing states 'Unregistered Sales of Equity Securities' as an item, but does not detail the nature of the offering.
What is the significance of the 'Financial Statements and Exhibits' being filed?
This indicates that updated financial information and supporting documents are being provided to the SEC.
What is Alzamend Neuro, Inc.'s primary business according to the SIC code?
Alzamend Neuro, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS' with SIC code 2834.
When is Alzamend Neuro, Inc.'s fiscal year end?
The company's fiscal year ends on April 30th (0430).
Filing Stats: 485 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-25 16:30:46
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
Filing Documents
- w9252538k.htm (8-K) — 24KB
- 0001214659-25-014200.txt ( ) — 187KB
- alzn-20250925.xsd (EX-101.SCH) — 3KB
- alzn-20250925_lab.xml (EX-101.LAB) — 33KB
- alzn-20250925_pre.xml (EX-101.PRE) — 22KB
- w9252538k_htm.xml (XML) — 4KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. Between September 17, 2025 and September 25, 2025, Alzamend Neuro, Inc. (the " Company ") issued an aggregate of 300,000 shares of common stock, par value $0.0001 per share (" Common Stock ") upon conversion of an aggregate of 696 shares of Series B Convertible Preferred Stock. The shares of Common Stock were issued in reliance upon exemption from the registration requirements under Section 4(a)(2) under the Securities Act. As of September 25, 2025, the Company had 3,439,861 shares of Common Stock outstanding.
01 Financial Statements And Exhibits
Item 9.01 Financial Statements And Exhibits (d) Exhibits: Exhibit No. Description 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: September 25, 2025 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel 3